Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued
Reference number: GID-TA10325
Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of guadecitabine for untreated acute myeloid leukaemia. However, the company have advised that the ASTRAL-1 study did not meet the co-primary endpoints of complete response (CR) rate or overall survival (OS). Therefore, NICE has decided to suspend this appraisal from its work programme.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes.